<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6358">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667003</url>
  </required_header>
  <id_info>
    <org_study_id>G1209</org_study_id>
    <nct_id>NCT01667003</nct_id>
  </id_info>
  <brief_title>BIOFLOW-III Sweden Satellite Registry</brief_title>
  <official_title>BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik ApS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik ApS</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring
      coronary revascularization with Drug Eluting Stents (DES).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal
      Coronary Angioplasty (PTCA) provides high initial procedural success. However, the medium to
      long-term complications range from rather immediate elastic recoil or vessel contraction to
      longer processes like smooth muscle cell proliferation and excessive production of extra
      cellular matrix, thrombus formation and atherosclerotic changes like restenosis or
      angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from
      30%-50%. Such rates of recurrence have serious economic consequences.

      Bare Metal Stents (BMS), designed to address the limitations of PTCA, reduced the
      angiographic and clinical restenosis rates in de novo lesions compared to PTCA alone and
      decreased the need for CABG. BMS substantially reduced the incidence of abrupt artery
      closure, but restenosis still occurred in about 20%-40% of cases, necessitating repeat
      procedures.

      The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by
      adding an antiproliferative drug (directly immobilised on the stent surface or released from
      a polymer matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly
      reduced the incidence of restenosis and resulted in a better safety profile as compared to
      BMS with systemic drug administration.

      These advantages and a lower cost compared to surgical interventions has made DES an
      attractive option to treat coronary artery disease. This observational registry is designed
      to investigate and collect clinical evidence for the clinical performance and safety of the
      Orsiro Drug Eluting Stent System in an all-comers patient population in daily clinical
      practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI), Emergent Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any repeat revascularization of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any repeat revascularization of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Device Success</measure>
    <time_frame>At time of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Procedural Success</measure>
    <time_frame>During the hospital stay to a maximum of the first seven days post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Orsiro DES</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers patient population with all subjects requiring coronary revascularization with
        a Drug Eluting Stent (DES)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic coronary artery disease

          -  Subject has signed informed consent for data release

          -  Subject is geographically stable and willing to participate at all follow-up
             assessments

          -  Subject is â‰¥ 18 years

        Exclusion Criteria:

          -  Subject did not sign informed consent for data release

          -  Pregnancy

          -  Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other
             anticoagulation /  antiplatelet therapy required for PCI, stainless steel, Sirolimus
             or contrast media

          -  Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be
             maintained

          -  Currently participating in another study and primary endpoint is not reached yet.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole Froebert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kardiologiska Kliniken</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gitte Wennecke</last_name>
    <phone>+45 2815 9195</phone>
    <email>gitte.wennecke@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centralsjukhuset i Karlstad</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Olsson, MD</last_name>
      <phone>+46 19-6021000</phone>
    </contact>
    <investigator>
      <last_name>Hans Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologiska Kliniken</name>
      <address>
        <city>Oerebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Josefsson</last_name>
      <email>johan.Josefsson@orebroll.se</email>
    </contact>
    <investigator>
      <last_name>Ole Froebert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyd University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Habib Mir- Akbari, MD</last_name>
      <phone>+46 8-655 67 86</phone>
    </contact>
    <investigator>
      <last_name>Habib Mir- Akbari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset i Uppsala</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan James, MD</last_name>
      <phone>+46 18-611 47 32</phone>
    </contact>
    <investigator>
      <last_name>Stefan James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 15, 2012</lastchanged_date>
  <firstreceived_date>August 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>International</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Observational registry</keyword>
  <keyword>Orsiro Drug Eluting Stent (DES)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Treatment of Coronary Artery Disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Angina</keyword>
  <keyword>Subgroups</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Small Vessels</keyword>
  <keyword>Chronic Total Occlusion (CTO)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
